Shandong Weigao Blood
Shandong Weigao Blood Purification Products Co., Ltd. engages in the research and development, production, and sale of blood purification medical products in China. It offers dialyzers, dialysis machines, hemodialysis machines, A.V. fistula needle sets, extracorporeal blood circuits, bloodlines, and plasma separators; peritoneal dialysis (PD) solutions; and PD consumables, such as bag free set, c… Read more
Market Cap & Net Worth: Shandong Weigao Blood (603014)
Shandong Weigao Blood (SHG:603014) has a market capitalization of $51.31K (CN¥376.50K) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #42221 globally and #4687 in its home market, demonstrating a 1.99% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shandong Weigao Blood's stock price CN¥39.54 by its total outstanding shares 9522 (9.52K).
Shandong Weigao Blood Market Cap History: 2025 to 2026
Shandong Weigao Blood's market capitalization history from 2025 to 2026. Data shows growth from $51.43K to $51.31K (0.00% CAGR).
Shandong Weigao Blood Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shandong Weigao Blood's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 603014 by Market Capitalization
Companies near Shandong Weigao Blood in the global market cap rankings as of March 18, 2026.
Key companies related to Shandong Weigao Blood by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Shandong Weigao Blood Historical Marketcap From 2025 to 2026
Between 2025 and today, Shandong Weigao Blood's market cap moved from $51.43K to $ 51.31K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥51.31K | -0.23% |
| 2025 | CN¥51.43K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Shandong Weigao Blood was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $51.31K USD |
| MoneyControl | $51.31K USD |
| MarketWatch | $51.31K USD |
| marketcap.company | $51.31K USD |
| Reuters | $51.31K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.